Follistatin 315 vs 344: How the Isoforms Differ

Short answer: FS-344 is not a second circulating protein competing with FS-315. It is the 344-residue precursor encoded by the longer FST transcript, and once its 29-residue signal peptide is removed during secretion, the mature protein that leaves the cell is FS-315. The shorter transcript encodes a 317-residue precursor that matures into FS-288. So follistatin 315 vs 344 describes one gene product at two stages, while FS-288 against FS-315 describes a genuine functional split.

That distinction matters because catalogue labels, gene transfer constructs and peer-reviewed papers all use different numbering conventions for the same material. A vial marked 'Follistatin 344' and a paper describing recombinant FS-315 can refer to the same mature chain. What follows maps the FST transcripts to their mature proteins, explains what the heparin-binding region does, compares activin and myostatin interactions across the family, and sets out how a laboratory confirms which isoform it actually holds.

What does the FST gene actually produce?

One gene, two principal messenger RNAs, and three protein forms found in tissue and serum. The human FST gene sits on chromosome 5 and is transcribed into two main transcripts named for the length of the precursor polypeptide each encodes: FST317 and FST344. Both precursors begin with the same 29-residue signal peptide, the address tag that routes a newly synthesised protein into the secretory pathway. Signal peptidase removes that tag, which is why the proteins recovered outside the cell measure 288 and 315 residues rather than 317 and 344.

The domain architecture is identical across follistatin isoforms. Each chain carries an N-terminal domain followed by three cysteine-rich follistatin domains, conventionally labelled FSD1, FSD2 and FSD3, each built from an EGF-like and a Kazal-like motif. The single structural difference between the two mature chains sits at the far C-terminus: the FST344 transcript retains a terminal exon encoding a short acidic tail that the FST317 transcript does not include.

That tail is the entire functional story. It does not change which transforming growth factor beta superfamily ligands follistatin can capture. It changes where the protein ends up after secretion. Anyone comparing follistatin 315 vs 344 on a specification sheet is almost always comparing a mature sequence count against a precursor count, not two distinct molecules.

Why is FS-344 described as a precursor rather than a circulating protein?

FS-344 has never been characterised as a species present in serum, because the 344-residue form exists only inside the secretory pathway before cleavage. Every intact molecule that reaches the extracellular space from the FST344 transcript is FS-315, with or without the later proteolytic trimming described below. Searching for FST344 in protein databases returns a transcript and precursor record, not a circulating analyte.

So why does the number 344 dominate so much of the discussion? Two reasons, and neither is biological. First, complementary DNA constructs are named for the full open reading frame, including the signal peptide, so a plasmid or viral vector carrying the follistatin coding sequence is written as FST344. A gene transfer construct built on that coding sequence has been investigated in early-phase human research on neuromuscular conditions, which pushed the FS-344 label into general circulation well outside molecular biology. Second, suppliers of recombinant material inherited the construct naming convention and printed it on labels.

This is the part most secondary summaries get wrong. They treat the FS-344 label as evidence of a distinct, longer, more potent protein, when the number simply counts 29 extra residues that are enzymatically discarded before the protein does anything. Reading follistatin 315 vs 344 as a potency comparison is a naming artefact, not a finding. Background on the parent compound page at Follistatin 344 covers the same point from the catalogue side.

How does alternative splicing generate FS-288, FS-303 and FS-315?

Alternative splicing explains two of the three mature forms. Proteolysis explains the third. The FST317 transcript omits the terminal exon that encodes the acidic C-terminal extension, producing FS-288 after signal peptide cleavage. The FST344 transcript retains it, producing FS-315. Both are genuine splice-derived isoforms.

FS-303 is not a splice variant, and describing it as one is the most frequent error in non-specialist write-ups of the follistatin isoforms. FS-303 arises after secretion, when proteases trim the C-terminal tail of FS-315, leaving a shortened chain with partially restored access to the heparin-binding region. It has been reported as abundant in gonadal tissue and follicular fluid, where follistatin regulates activin signalling locally rather than systemically.

A further layer of heterogeneity sits on top of the sequence itself. Follistatin carries N-linked glycosylation sites, so mammalian-expressed material arrives as a mixture of glycoforms while bacterially expressed material does not. Two vials labelled with the same residue count can therefore differ in apparent molecular weight on a gel or a mass spectrum without either label being wrong. The peptide terminology reference sets out how precursor, mature chain and glycoform designations are used in documentation.

What does the heparin-binding region change about where each isoform sits?

The heparin-binding region determines whether a follistatin molecule travels or stays put. A cluster of basic residues within FSD1 binds heparan sulfate proteoglycans on cell surfaces and in the extracellular matrix. In FS-288 that cluster is fully exposed, so the protein associates rapidly with the cell surface, acts as a local, matrix-anchored ligand trap, and is then internalised and degraded through the lysosomal route.

In FS-315 the acidic C-terminal tail folds back across the basic cluster and masks it. The consequence is a protein that stays soluble and is reported as the predominant follistatin species in serum, consistent with an endocrine-style distribution rather than a strictly local one. FS-303 sits between the two, with partial heparin affinity and a tissue-associated distribution.

That positional difference also drives clearance behaviour, because a protein bound to cell surface proteoglycans is removed from circulation faster than one that remains free in plasma. Comparative kinetics across the isoforms are discussed further in the half-life and research dynamics overview.

The practical reading of follistatin 315 vs 344, then, is that the label tells a researcher almost nothing about localisation. The label FS-288 against FS-315 tells them a great deal.

How do the isoforms interact with activin and myostatin?

All mature follistatin forms bind activin A with extremely high affinity, and structural work on the complex describes two follistatin molecules wrapping a single activin dimer in a 2:1 arrangement that occludes both the type I and type II receptor binding epitopes. The interaction is characteristically described as effectively irreversible under physiological conditions, which is why follistatin is used in laboratory work as an activin trap rather than a competitive modulator.

The same binding surfaces capture other transforming growth factor beta superfamily ligands with lower affinity, including myostatin, also written as GDF-8, along with GDF-11 and several bone morphogenetic proteins. Ligand selectivity is broadly shared across the isoforms. What differs is the effective local concentration: FS-288 concentrates at the cell surface where myostatin and activin receptors are located, and several cell-based reports describe it as the more effective neutraliser in that setting, while FS-315 distributes through the medium or the circulation instead.

One related protein is worth separating out. FSTL3, also called FLRG, is the product of a different gene, binds activin and myostatin, and lacks a heparin-binding region altogether. It is not a follistatin isoform and should not be grouped with FS-288, FS-303 or FS-315 in a comparison. The mechanism side of this is expanded in the myostatin inhibition research guide.

How do the follistatin isoforms compare side by side?

The table below collapses origin, localisation and binding behaviour into one view, because most confusion in this area comes from comparing attributes that belong to different levels of description. Precursor counts and mature counts are listed separately for that reason.

Follistatin 315 vs 344: what do the numbers on a research label actually mean?

A label is a naming convention, not a specification, and the only document that resolves it is the certificate of analysis. When a supplier lists 'Follistatin 344', the standard reading is recombinant protein corresponding to the FST344-derived chain, which in mature secreted form is 315 residues. When a paper reports experiments with FS-315, it is describing that same mature chain using the post-cleavage count. Reading follistatin 315 vs 344 as two separate products to choose between leads directly to duplicated purchasing.

What should be checked instead is concrete: the stated amino acid sequence or residue count, the expression system, whether any purification tag remains attached, and the observed mass on the analytical record. A C-terminal tag or an uncleaved fusion partner shifts mass and can interfere with the acidic tail behaviour that defines FS-315 in the first place. Real Peptides publishes lot certificates of analysis at the COA library, and the walkthrough at how to read a follistatin 344 COA explains which fields answer the isoform question and which do not.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption. Nothing here is guidance for a person or an animal; anyone with a health question should talk to their physician or veterinarian rather than treating a research reference page as advice.

How do FS-288 and FS-315 behave differently in cell culture?

In a cell-based assay the two mature isoforms do not stay in the same place, and that single fact changes how results are interpreted. FS-288 added to culture medium partitions rapidly onto heparan sulfate proteoglycans on the cell surface and onto matrix coatings such as fibronectin or laminin, so the concentration remaining in the supernatant falls while the concentration at the receptor interface rises. FS-315 largely stays in the medium.

The practical consequence is that a soluble assay comparing fs-288 fs-315 activity at equal nominal medium concentrations is not comparing equal effective concentrations at the membrane. Heparin present in a buffer compounds the problem by competing for the same basic cluster and stripping FS-288 off the surface. Matched-isoform controls and a stated matrix condition are what make such comparisons readable.

This is also where the follistatin 315 vs 344 label question stops being semantic. If a protocol was built around surface-anchored FS-288 and the material on the bench is FS-315 sold under a 344 label, the experiment is modelling soluble ligand sequestration rather than local matrix-bound trapping. The two answer different questions about activin and myostatin signalling.

How can a laboratory confirm which follistatin isoform is in a vial?

Identity for a protein of this size is confirmed by mass, not by appearance. Intact mass measurement by mass spectrometry separates a 288-residue chain from a 315-residue chain unambiguously, and peptide mapping after enzymatic digestion confirms whether the C-terminal acidic segment is present. Reversed-phase HPLC reports chromatographic homogeneity and retention behaviour but will not, on its own, tell a researcher which isoform eluted.

Glycosylation complicates the reading when the expression system is mammalian, because glycoforms spread the intact mass into a cluster of peaks rather than a single value. Deglycosylation before analysis, or a stated expression system on the certificate, resolves that. Comparative background on the two main analytical methods sits in HPLC versus mass spectrometry for peptides and mass spectrometry peptide verification.

Storage history belongs in the identity question too. Follistatin is a disulfide-rich multi-domain protein rather than a short linear chain, so loss of structure through freeze-thaw cycling or moisture exposure can change binding behaviour while leaving sequence identity intact. A record of handling conditions is part of knowing what is in the vial, as set out in the storage, stability and handling guide.

What if the documentation and the literature disagree?

What if the label says 344 but the listed sequence is 315 residues?

Treat the 315-residue sequence as the authoritative description of the material. The label is naming the coding sequence, including the signal peptide, while the sequence field is describing the mature chain that was actually expressed and purified. This is the expected pattern for recombinant follistatin, not a documentation error, and it is the single most common reason researchers believe they have received the wrong isoform.

What if a published protocol used FS-288 and the available material is FS-315?

Treat the two as non-interchangeable and record the substitution in the method. The ligand selectivity overlaps heavily, but the localisation does not, so a surface-trapping protocol run with FS-315 measures a different compartment. Comparisons against the original report should be framed as soluble-phase rather than matrix-associated, and any heparin in the buffer system should be noted explicitly.

What if two vials with identical labels show different masses?

Check the expression system before assuming a labelling fault. Bacterially expressed follistatin is non-glycosylated and gives a tighter intact mass, while mammalian-expressed material gives a glycoform distribution at higher apparent mass. Residual purification tags and C-terminal trimming toward an FS-303-like species are the other two routine explanations, and all three are visible on a well-reported certificate.

How we researched this page

This page was assembled from published literature and public sequence databases only. The sources used were peer-reviewed reproductive endocrinology and structural biology work describing follistatin domain architecture, the follistatin-activin complex and heparan sulfate interaction, together with public gene and protein records for the human FST locus and its transcript variants. Reviews covering follistatin as a transforming growth factor beta superfamily antagonist were used to cross-check isoform nomenclature.

No first-party laboratory testing, assay work or in-house characterisation informed any statement here. Where the literature reports a finding in animal or cell models rather than in humans, that limitation is stated in the text rather than smoothed over. Numbers have been included only where they are structural facts of the sequence, such as residue counts and signal peptide length, and omitted entirely where a precise figure could not be verified. Regulatory framing follows the research use only definition.

What the isoform literature still does not settle

Here is the honest answer: the isoform distinction is well characterised at the level of sequence, heparin binding and ligand capture, and much thinner at the level of what either form does over time in a whole organism. The circulating-versus-bound split rests substantially on cell and animal model work. Comparative human kinetics across FS-288, FS-303 and FS-315 are not characterised in the way the naming confidence implies. Anything claiming a settled physiological ranking between the mature isoforms is overstating the record, and the follistatin 315 vs 344 framing in particular compares a protein to its own precursor.

Related reading across this site includes the hub page on what follistatin is, the overview of what follistatin 344 is, the mechanism explainer on how follistatin 344 works, the naming question addressed in is follistatin the same as follistatin 344, the body composition research summary, the sarcopenia research overview, the long-term research observations page, the legal and regulatory status explainer, and three compound comparisons covering follistatin 344 against IGF-1 LR3, follistatin 344 against sermorelin and follistatin 344 against MK-677. On documentation and handling, see how to read a COA for peptides, HPLC peptide purity, peptide purity levels and research quality standards, the peptide storage best practice guide, peptide degradation pathways, lyophilized versus liquid stability, and understanding peptide sequences and amino acid codes.

The cleanest way to retire the follistatin 315 vs 344 confusion is to stop treating the numbers as a ranking and start treating them as coordinates. One counts a precursor inside the cell, the other counts the chain that reaches the outside world, and neither number tells you the thing that actually changes an experiment: whether the heparin-binding cluster in FSD1 is exposed or masked. Two researchers can hold identical material under different labels and reach different conclusions purely because one buffer contained heparin. The sequence is settled science. The documentation is where the real variability lives.